PDGI Pharmanet Development Grp (MM)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

——————— ^_

FORM 8-K

———————

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):   March 17, 2009

———————

PharmaNet Development Group, Inc.

( Exact Name of Registrant as Specified in Charter)

———————

Delaware	001-16119	59-2407464
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

504 Carnegie Center, Princeton, NJ 08540

(Address of Principal Executive Offices) (Zip Code)

(609) 951-6800

(Registrant’s telephone number, including area code)

 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

---

ITEM 8.01.  Other Events.

On March 17, 2009, PharmaNet Development Group, Inc., a Delaware corporation, provided notice to holders of its 2.25% Convertible Senior Notes due 2024 of the anticipated effective date of a “Fundamental Change” (as defined in the Indenture). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

Exhibit No.		Description
99.1		Press Release dated March 17, 2009 of PharmaNet Development Group, Inc.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 17, 2009

	PHARMANET DEVELOPMENT GROUP, INC.
	By:	/s/ J OHN P. H AMILL
		Name: John P. Hamill
		Title:  EVP and Chief Financial Officer